Behavioral
Assessment of depression
Assessment of depression is a behavioral intervention with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
BEHAVIORAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Not yet recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (50.0%)
N/A1 (50.0%)
Trials by Status
completed133%
not_yet_recruiting133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT03947216
not_yet_recruiting
Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT06754553
terminatednot_applicable
Functional Imaging of Psychic Pain
NCT01493323
Clinical Trials (3)
Showing 3 of 3 trials
NCT03947216Phase 2
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT06754553
Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT01493323Not Applicable
Functional Imaging of Psychic Pain
All 3 trials loaded
Drug Details
- Intervention Type
- BEHAVIORAL
- Total Trials
- 3